K. Tuberculosis and other Mycobacterial Infections

1388 - Epidemiology and Treatment Outcomes of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States

1389 - Nontuberculous Mycobacterial Infections of the Upper Extremity

1390 - Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?

1391 - Body Mass Index and Leptin Levels at Different Stages of the Tuberculosis Spectrum

1392 - Nontuberculous mycobacteria isolated from Wisconsin residents, 2010-2018

1393 - Loss to Follow-up Rate in the Treatment of Latent Tuberculosis by Region of Origin

1394 - Autochthonous leprosy in Missouri

1395 - Epidemiology of Non-Tuberculous Mycobacteria Infection Among Immunocompromised Children : A Single Center Experience

1398 - Gland tuberculosis: a rare localization of tuberculosis

1399 - Clarithromycin–rifampin-based treatment for non-tuberculous mycobacterial infections in immunocompromised patients who require concomitant CYP-metabolized medications

1400 - Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project

1401 - Infliximab for Immune Reconstitution Inflammatory Syndrome (IRIS) in Tuberculous Meningitis; A Treatment Paradox

1402 - NTM Infections; A Rising Global Health Problem / Clinical Characteristics and Outcomes of Patients with Non-Tuberculous Mycobacterial Infections at Two Tertiary Academic Medical Centers

1403 - Tuberculous sacroiliitis: Clinical and imaging characteristics

1404 - Tuberculosis and HIV coinfection: a review of 135 cases Experience of the infectious diseases department- CHU Mohamed VI- Marrakech

1405 - The accuracy of Mycobacterium tuberculosis specific IFN-γ/IL-2/TNF-α- FluoroSpot in differential diagnosis of active tuberculosis and latent tuberculosis infection: a case-control study

1406 - Hepatitis B and C Prevalence in Patients with Active and Latent Tuberculosis in an Ethnically Diverse Area of London, UK

1407 - The Latent Tuberculosis Infection Cascade of Care during the COVID-19 Pandemic Response in a Mid-Sized US City

1408 - Population-based Nontuberculous Mycobacteria Surveillance in Four Emerging Infections Program Sites, October 2019–March 2020

1409 - Pulmonary Non-tuberculous Mycobacterium Infection (PNTMI) and COVID-19: Characterization of the National COVID Collaborative Cohort (N3C)

1410 - Isoniazid therapy for latent tuberculosis infection in patients with cancer treated with checkpoint inhibitors immunotherapy

1411 - Noninvasive Assessment of Intralesional Antimicrobial Concentration-Time Profiles in Pulmonary and Central Nervous System Tuberculosis using Dynamic ¹⁸F-Pretomanid Positron Emission Tomography

1412 - Clinical Epidemiology and Characteristics of Pulmonary Nontuberculous Mycobacterial Isolates from a Large Academic Military Treatment Facility